BioCentury | Jan 12, 2017
Clinical News

Onapristone: Ph II halted

...its board is evaluating all development, strategic or corporate opportunities available for onapristone, AR-42 and AR-12...
...completed a Phase I trial of AR-12 for advanced or recurrent solid tumors or lymphoma. AR-12...
BioCentury | Nov 2, 2015
Clinical News

Arno preclinical data

...the North American Cystic Fibrosis meeting in Phoenix. AR-13 is an analog of the company’s AR-12...
BioCentury | May 11, 2015
Clinical News

AR-12 regulatory update

...The European Commission granted Orphan Drug designation to AR-12 from Arno to treat cryptococcosis and tularemia...
...or recurrent solid tumors or lymphoma. Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Product: AR-12 (formerly OSU-03012...
BioCentury | Sep 11, 2014
Distillery Therapeutics

Indication: Neurology

...malignancies and in Phase I testing to treat solid tumors. Arno Therapeutics Inc. has AR-12 (OSU-03012...
BioCentury | Oct 17, 2013
Distillery Therapeutics

Indication: Cancer

...steps include identifying human melanomas that might respond to PDPK1 inhibitors. Arno Therapeutics Inc. has AR-12...
BioCentury | Sep 19, 2013
Distillery Therapeutics

Indication: Neurology

...and analyzing how PDPK1 is activated by pathogenic prions and amyloid peptides. Arno Therapeutics Inc.'s AR-12...
BioCentury | Mar 21, 2013
Distillery Therapeutics

Indication: Cancer

...steps could include testing clinical-stage PDK1 inhibitors in mouse models for PDAC. Arno Therapeutics Inc.'s AR-12...
BioCentury | Dec 9, 2010
Distillery Therapeutics

Indication: Cancer

...cancer models. Pfizer Inc. markets Rapamune rapamycin (sirolimus) to prevent organ rejection in renal transplantation. AR-12...
BioCentury | Sep 7, 2009
Clinical News

AR-12: Phase I started

...Arno began an open-label, dose-escalation, U.S. and European Phase I trial to evaluate oral AR-12 given...
...days in up to 50 patients. Arno Therapeutics Inc. (OTCBB:ARNI), Fairfield, N.J. Product: AR-12 (formerly OSU-03012...
BioCentury | Jun 9, 2008
Finance

Ebb & Flow

...and hematological cancers. In addition, the company hopes to submit INDs for preclinical oncology compounds AR-12...
Items per page:
1 - 10 of 11